Keryx Biopharmaceuticals Inc fka KERX

[califax]

KERX - 2010 NEWS (updated)

01/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=40967159&symbol=NASDAQ%3AKERX

Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in patients with end-stage renal disease (ESRD)

##################################################################

01/25/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41242064&symbol=NASDAQ%3AKERX

Keryx Reports Statistically Significant Benefit in Survival from Updated Results on the clinical activity of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colon cancer.

##################################################################

01/29/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41314106&symbol=N^KERX

Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's")

##################################################################

02/03/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41377888&symbol=N^KERX

Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in patients with refractory metastatic colorectal cancer.

##################################################################

04/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42251074&symbol=N^KERX

Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer

##################################################################

04/08/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42299718&symbol=N^KERX

Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer

##################################################################

04/15/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42392688&symbol=N^KERX

Keryx Biopharmaceuticals Reports Updated Long-Term Data of Zerenex (ferric citrate) Presented at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings

##################################################################

Date : 05/06/2010 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&article=42688680&symbol=KERX

Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patients with Hyperphosphatemia

##################################################################

Date : 05/17/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42848470&symbol=N^KERX

Publication in the Journal of the National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential in Neuroblastoma Tumors

##################################################################

Date : 05/21/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42926420&symbol=N^KERX

Keryx Biopharmaceuticals Announces Presentation of Two Abstracts at ASCO 2010 Annual Meeting

##################################################################